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Abstract Unlike mammalian lysosomal cysteine proteases, the
trypanosomal cysteine protease cruzipain contains a 130-amino
acid residue C-terminal domain, in addition to the catalytic
domain, and it is stable at neutral pH. The endogenous (with
C-terminal domain) and recombinant (without C-terminal
domain) cruzipains exhibit similar stabilities at both acid
(kinac = 3.1U1033 s31 and 4.4U1033 s31 at pH 2.75 for
endogenous and recombinant cruzipain, respectively) and alka-
line pH (kinac = 3.0U1033 s31 and 3.7U1033 s31 at pH 9.15 for
endogenous and recombinant cruzipain, respectively). The pH-
induced inactivation, which is a highly pH dependent first
order process, is irreversible and accompanied by significant
changes of secondary and tertiary structure as revealed by
circular dichroism measurements. The different stability of
cruzipain as compared to related proteases, is therefore due
mainly to the different number, nature and distribution of
charged residues within the catalytic domain and not due to
addition of the C-terminal domain.
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1. Introduction
The parasite-derived proteases have received considerable
attention during the last decade due to their participation in
the pathogenesis and survival of the parasite [1,2]. The proto-
zoan parasite Trypanosoma cruzi is the causative agent of the
American trypanosomiasis, Chagas’ disease, which is trans-
mitted to a mammalian host from the bite of an infected
blood-sucking triatomine bug (reviewed in [3]). Cruzipain
[4], also known as GP57/51 [5] or cruzain [6], is the major
cysteine protease of T. cruzi and belongs to the papain family.
The enzyme may participate in parasite nutrition [7], penetra-
tion into the host cells [8], pathogenesis and replication of the
parasite [9], activation of plasma prekallikrein in the host [10]
and protein breakdown [11].
The cruzipain gene encodes a protein containing a prepro-
region, a catalytic domain and a C-terminal extension [6,12].
Evidence was presented that the C-terminal domain may be
autocatalytically removed [13]. In recombinant cruzipain, ex-
pressed in Escherichia coli as a fusion polypeptide, autoacti-
vation was accompanied by proteolytic removal of the pro-
domain and the C-terminal extension [6,14].
Only cysteine proteinases from Trypanosomatids share an
unusual 100^130-amino acids long C-terminal domain
[6,15,16]. This domain is not required for protein folding,
enzyme catalysis [6] and tra⁄cking [17]. Its precise role is
unknown, but it may signi¢cantly enhance the catalytic e⁄-
ciency of these proteinases [10] and is also known to be the
major immunogenic part of cruzipain [18]. Cruzipain is sub-
stantially more stable and active at neutral pH than the re-
lated cathepsins B and L [19^23], although the three-dimen-
sional structures of the catalytic parts of the three enzymes are
highly similar [24^27], suggesting that the C-terminal domain
may play a role in cruzipain stability, as well as in parasite
survival under the physiological conditions of the host. There-
fore, the aim of this study was to investigate the role of pH in
the regulation of cruzipain activity, as well as the possible
contribution of the C-terminal domain to enzyme stability.
We demonstrate here that the higher stability of cruzipain
at neutral pH compared to related proteases is mainly due
to di¡erent charged residues within the catalytic domain and
not due to addition of the C-terminal domain.
2. Materials and methods
2.1. Materials
The substrate Z^Phe^Arg^MCA was purchased from the Peptide
Research Institute (Japan). N-(2-Hydroxyethyl)piperazine-NP-(2-eth-
anesulfonic acid) (HEPES) and glycine were provided by Serva (Ger-
many). Dithiothreitol and ethylenediamine tetraacetic acid (EDTA)
were obtained from Sigma (USA). Dimethyl sulfoxide was from
Merck (Germany). All other chemicals were of analytical grade. Stock
solution of the substrate was prepared in dimethyl sulfoxide.
Cruzipain was isolated from T. cruzi epimastigotes, Tulahue¤n
strain, Tul 2 stock [19]. Recombinant cruzipain, lacking the C-termi-
nal extension, was expressed in E. coli as described earlier [14]. Protein
concentration was determined from absorbance measurements by the
method of Pace et al. [28].
The following bu¡ers were used in kinetic experiments: 50 mM
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citrate from pH 2.25 to 3.6, 50 mM sodium acetate from pH 3.7 to
5.6, 100 mM phosphate from pH 5.7 to 7.5, 50 mM HEPES from pH
7.6 to 8.5, 50 mM glycine from pH 8.6 to 10.3 and 50 mM boric acid/
NaOH at pH 12.0. The assay bu¡er was 100 mM phosphate bu¡er,
pH 7.0. All bu¡ers contained 1 mM EDTA and 0.1 M NaCl.
2.2. Inactivation kinetics
The kinetics of inactivation of endogenous and recombinant cruzi-
pain was studied at acidic and alkaline pH by continuous and dis-
continuous methods essentially as described previously [20,29]. All
kinetic experiments were performed at 37‡C, if not otherwise stated.
Prior to the experiments, cruzipain was activated with 2 mM dithio-
threitol as described [19,20]. The concentration of dimethyl sulfoxide
was adjusted to 3% (v/v), unless otherwise stated, and substrate con-
sumption was less than 5%.
2.3. Reversibility of inactivation
The reversibility of the pH-induced inactivation of cruzipain was
studied at 37, 25 or 5‡C as follows. 5 Wl of cruzipain (0.1 WM) were
added to 95 Wl of prewarmed bu¡er (37‡C) at pH 2.25 or 10.0 and
incubated at the same temperature for di¡erent times. 20 Wl were
neutralized with 180 Wl of thermostated assay bu¡er (pH 7.0; 37‡C,
25‡C or 5‡C) and 5 Wl aliquots were taken at appropriate time inter-
vals to measure the residual activity, as described [21]. In the control
experiments the enzyme was diluted into the assay bu¡er.
2.4. Circular dichroism
Cruzipain was inactivated at pH 2.3 and 10.3. The far-UV and
near-UV circular dichroism spectra of active and inactivated cruzipain
samples were recorded at 25‡C with an AVIV 62 DS spectropolarim-
eter (Lakewood, NJ, USA) as described [30].
3. Results
3.1. Inactivation kinetics at acidic pH
The exposure of endogenous and recombinant cruzipain to
pH 2.75 in the presence of substrate resulted in an exponential
decrease of activity monitored by the release of the £uorescent
MCA product (Fig. 1). The progress curves recorded could be
best described by the simple ¢rst-order rate equation [20]. The
substrate consumption was below 5% indicating that the de-
crease of activity was a result of a pH-induced inactivation.
Also in the absence of substrate, the cruzipain activity at pH
2.75, monitored by a discontinuous method, progressively de-
creased in agreement with a single exponential decay.
Inactivation of both cruzipain forms was studied at pH 2.75
as a function of enzyme concentration by the continuous
method. In the range covered (0.5^5 nM) the observed inacti-
vation rate constant (kobs) was independent of enzyme con-
centration (kobs = 19.7 þ 0.2U1034 s31 and 18.6 þ 0.1U1034
s31 for endogenous and recombinant cruzipain, respectively),
indicating that the reaction is ¢rst order. In addition, this
independence of enzyme concentration indicated that autoly-
sis was not responsible for the enzyme inactivation. However,
under the same conditions, the kobs of both enzymes decreased
with increasing substrate concentration (2.5^102.5 WM Z^
Phe^Arg^MCA; Fig. 2), indicating that the enzyme^substrate
complex is substantially more stable than the enzyme alone.
The substrate dependence of the kobs values could be de-
scribed by the following competitive mechanism [20].
where E and E* represent active and inactive enzyme, respec-
tively, S stands for substrate and P for product. As can be
seen, this model could be adequately ¢tted to the experimental
data (Fig. 2), giving the best estimates of 3.1 þ 0.1U1033 s31
and 4.2 þ 0.2U1033 s31 for the substrate-independent true
inactivation rate constant kinac, and of 35 þ 4 WM and 25 þ 4
WM for the Km for endogenous and recombinant cruzipain,
respectively. At the same pH, the values of kinac, determined
by the discontinuous method, were almost identical
(3.1U1033 s31 and 4.4U1033 s31 for endogenous and re-
combinant cruzipain, respectively).
3.2. E¡ect of pH and temperature on the inactivation rate
constant
The inactivation process was studied at acidic pH (2.25^4.0)
and alkaline pH (7.5^10.0). The rate of inactivation increased
V7300-fold from pH 4.0 to 2.25 and V600-fold from pH 7.5
to 10.0 (Table 1). In the rate limiting step of the inactivation
process 2.3 þ 0.2 protons were adsorbed at acidic pH and
0.95 þ 0.02 proton was desorbed at alkaline pH, as calculated
from the slopes of the plot of log kinac vs. pH [31] for endog-
enous cruzipain (not shown). The lack of a plateau in this plot
Fig. 1. Inactivation of endogenous and recombinant cruzipain at
pH 2.75 and 37‡C in the presence of substrate. The experimental
data were ¢tted using the equation F = Fr (13e3kobs t) þ Fo where F
and Fr represent the £uorescence measured at time t or in¢nite
time and Fo stands for the background £uorescence. The values
kobs = 2.70 þ 0.02U1033 s31 for recombinant cruzipain (a) and
kobs = 2.45 þ 0.04U1033 s31 for endogenous cruzipain (b) were ob-
tained. The enzyme and substrate concentrations were 0.5 nM and
25 WM, respectively.
Table 1
Rates of inactivation of endogenous and recombinant cruzipain
under acidic and alkaline conditions
pH Endogenous cruzipain
103Ukinac (s31)
Recombinant cruzipain
103Ukinac (s31)
2.15 24.7 þ 0.1 50.6 þ 0.1
2.50 7.2 þ 0.2 22.1 þ 0.1
2.75 3.1 þ 0.1 4.4 þ 0.3
3.00 0.45 þ 0.03 N.D.
3.25 0.13 þ 0.01 N.D.
3.50 0.028 þ 0.002 N.D.
4.00 0.0032 þ 0.0003 N.D.
7.50 0.028 þ 0.001 N.D.
8.00 0.18 þ 0.01 N.D.
8.50 0.53 þ 0.03 N.D.
9.15 3.0 þ 0.1 3.7 þ 0.4
9.50 3.1 þ 0.5 7.1 þ 0.4
10.00 16.8 þ 1.1 N.D.
The best estimates for kinac are given with their standard errors. Ex-
perimental conditions are given in Section 2.
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indicated that the pKa values of the ionizing groups involved
in the rate limiting step of the inactivation process were be-
tween 4.0 and 7.5. The inactivation rate constants of recombi-
nant cruzipain, determined in the absence of substrate, were
up to three-fold higher than those for endogenous cruzipain
(Table 1) showing a small stabilizing e¡ect of the C-terminal
domain.
The temperature-dependence of the inactivation rate con-
stant was studied in the range 5^37‡C at pH 2.25 and 10.0.
The rate of inactivation of endogenous cruzipain in this range
increased V870-fold at pH 2.25 and V545-fold at pH 10.0.
From the slope of the Arrhenius plot (not shown), activation
energies, of 177 þ 7 kJ mol31 and 172 þ 10 kJ mol31 at pH
2.25 and pH 10.0, respectively, were calculated.
3.3. Circular dichroism
The inactivation of cruzipain at pH 2.3 and pH 10.3 was
accompanied by substantial conformational changes, as
shown by far-UV circular dichroism spectra (Fig. 3). The
far-UV CD spectrum of native cruzipain at pH 6.5 is charac-
terized by a minimum at 213 nm, whereas a blue shift to 211
nm at pH 2.3 and to 206 nm at pH 10.3 was observed (Fig. 3).
At both extreme pH values, a 50^60% decrease in K-helix
content occurred, as judged by the CONTIN method [32].
Similarly, substantial changes were observed in the near-UV
CD spectra (not shown).
3.4. Reversibility and light scattering studies
The reversibility of cruzipain inactivation at pH 2.25 and
pH 10.0 was studied by exposing the enzyme to the inactiva-
tion bu¡er at 37‡C for di¡erent times and then rapidly neu-
tralizing the solution. No regain of activity was detected from
the completely inactivated enzyme, and the increase in cata-
lytic activity after shorter inactivation times never exceeded
10%. Since very low catalytic activity was recovered at
37‡C, the renaturation studies were also followed at 25‡C
and 5‡C. Nevertheless, the regain of activity was found to
be similarly low at these temperatures, suggesting that the
pH changes induced irreversible structural changes.
4. Discussion
In order to investigate the role of the C-terminal domain in
cruzipain pH-stability, inactivation experiments were per-
formed with endogenous cruzipain and a recombinant form
of the enzyme lacking the C-terminal domain. The pH-in-
duced inactivation of both cruzipain variants was shown to
be a ¢rst order process. The rate of inactivation of both var-
iants decreased with increasing substrate concentration, indi-
cating that the enzyme^substrate complex is substantially
more stable than the enzyme itself. However, the Km value
wasV30-fold greater at pH 2.75 (Km values of 35 þ 4 WM and
25 þ 4 WM for endogenous and recombinant cruzipain, respec-
tively) than at pH 5.8 (Km value of 0.96 WM; [14]), indicating
that the substrate-protective e¡ect is stronger closer to neutral
pH. The very good agreement of the kinac in the presence and
absence of substrate indicated that the results are independent
of the method used. The inactivation rate constants for both
cruzipain variants were similar in the whole pH range studied
(Table 1), indicating that the C-terminal domain of cruzipain
has very little e¡ect on the stability of the enzyme. However, a
strong dependence of kinac on pH indicated on importance of
ionic interactions for the stability of the enzyme.
The inactivation process was accompanied by signi¢cant
changes in secondary and tertiary structure, as revealed by
circular dichroism measurements. These structural changes
are in agreement with the high activation energy for the in-
activation of cruzipain under both pH conditions (V175 kJ/
mol) and with that for the inactivation of other related en-
zymes like cathepsins B [21] and L [20,29]. The structural
changes of endogenous cruzipain as well as the loss of cruzi-
pain activity, were irreversible due to enzyme aggregation.
These observations indicate that the C-terminal domain also
Fig. 2. E¡ect of substrate concentration on kobs, measured in the
presence of substrate, at pH 2.75 and 37‡C. The experimental data
were ¢tted using the equation kobs = kinac/(1+[S]/Km) [20], and the
best estimates of kinac = 3.1 þ 0.1U1033 s31 and Km = 35 þ 4 WM for
endogenous cruzipain (b) and kinac = 4.2 þ 0.2U1033 s31 and
Km = 25 þ 4 WM for recombinant cruzipain (a), respectively, were
obtained.
pH K-helix L-structure Remainder
2.3 0.09 þ 0.01 0.50 þ 0.01 0.42 þ 0.01
6.5 0.24 þ 0.01 0.43 þ 0.01 0.33 þ 0.01
10.3 0.12 þ 0.01 0.40 þ 0.01 0.48 þ 0.01
Fig. 3. Far-UV CD spectra of endogenous cruzipain at acidic, neu-
tral and alkaline pH. Experimental conditions were as described in
Section 2. The spectra were obtained at pH 2.3 (dashed), pH 6.5
(solid) and pH 10.3 (dotted). The enzyme concentration was 1 WM.
Calculations by CONTIN method [32], gave the following fractions
of secondary structural elements:
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is not important for the reversibility of pH-induced inactiva-
tion.
Inactivation of both cruzipain variants is consistent with
the mechanism, where inactivation starts in the active site
region with disruption of the Cys^His active site ion pair
and is followed by domain separation and further unfolding
of the enzyme [21]. The di¡erent pH-stabilities of papain-like
cysteine proteinases are probably a result of di¡erent number,
nature and distribution of charged residues.
The high stability of cruzipain at neutral pH may have an
important role in the physiological survival of the parasite. It
is known that the survival of T. cruzi after human infection
depends on the developmental stage [33]. Moreover, the pres-
ence of active cruzipain on the cell surface of amastigotes and
trypomastigotes [34] might be relevant to the escape of the
parasite from the phagosome and replication in the cyto-
plasm. The C-terminal domain may be involved in parasite
survival as the major immunogenic part of the cruzipain mol-
ecule [18]. After human infection, the antibodies formed are
probably directed to the C-terminal domain [5] and as a con-
sequence, the catalytic part of cruzipain might not be inhib-
ited by circulating protein inhibitors, due to the steric hin-
drance. The resulting immunocomplexes are as enzymatically
active as the free enzyme. The structural bifunctionality of
cruzipain, consisting of a highly stable catalytic domain and
a highly antigenic C-terminal domain [18], may be essential
for the parasite survival after host invasion. These studies
contribute to the understanding of the higher stability of cru-
zipain compared to related mammalian lysosomal cysteine
proteases, although the function of the C-terminal domain
remains as yet unknown.
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